Elevai Labs (NASDAQ:ELAB – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap multi-sector conglomerates companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.
Profitability
This table compares Elevai Labs and Arvinas’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Elevai Labs | -223.41% | -124.93% | -85.10% |
Arvinas | -75.51% | -33.75% | -16.75% |
Volatility and Risk
Elevai Labs has a beta of -2.95, suggesting that its share price is 395% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Elevai Labs | 0 | 0 | 0 | 0 | 0.00 |
Arvinas | 0 | 5 | 11 | 0 | 2.69 |
Arvinas has a consensus target price of $37.47, indicating a potential upside of 344.97%. Given Arvinas’ stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Elevai Labs.
Earnings & Valuation
This table compares Elevai Labs and Arvinas”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Elevai Labs | $2.45 million | 1.11 | -$4.30 million | ($433.87) | -0.01 |
Arvinas | $263.40 million | 2.20 | -$198.90 million | ($2.77) | -3.04 |
Elevai Labs has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
22.2% of Elevai Labs shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 0.6% of Elevai Labs shares are held by insiders. Comparatively, 5.2% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Arvinas beats Elevai Labs on 12 of the 14 factors compared between the two stocks.
About Elevai Labs
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
About Arvinas
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Receive News & Ratings for Elevai Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevai Labs and related companies with MarketBeat.com's FREE daily email newsletter.